Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.

Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, Dheda K, Dudnyk A, Farhat MR, Gagneux S, Grobusch MP, Gröschel MI, Guglielmetti L, Kontsevaya I, Lange B, van Leth F, Lienhardt C, Mandalakas AM, Maurer FP, Merker M, Miotto P, Molina-Moya B, Morel F, Niemann S, Veziris N, Whitelaw A, Horsburgh CR Jr, Lange C, TBnet and RESIST-TB networks

Open source

DOI: 10.1016/s1473-3099(22)00875-1
Published: 2023 Apr
Container: The Lancet. Infectious diseases
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1473-3099-22-00875-1,
  title = {Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.},
  author = {Domínguez J and Boeree MJ and Cambau E and Chesov D and Conradie F and Cox V and Dheda K and Dudnyk A and Farhat MR and Gagneux S and Grobusch MP and Gröschel MI and Guglielmetti L and Kontsevaya I and Lange B and van Leth F and Lienhardt C and Mandalakas AM and Maurer FP and Merker M and Miotto P and Molina-Moya B and Morel F and Niemann S and Veziris N and Whitelaw A and Horsburgh CR Jr and Lange C and TBnet and RESIST-TB networks},
  year = {2023},
  journal = {The Lancet. Infectious diseases},
  doi = {10.1016/s1473-3099(22)00875-1},
  url = {https://doi.org/10.1016/s1473-3099(22)00875-1}
}

RIS

TY  - JOUR
TI  - Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
AU  - Domínguez J
AU  - Boeree MJ
AU  - Cambau E
AU  - Chesov D
AU  - Conradie F
AU  - Cox V
AU  - Dheda K
AU  - Dudnyk A
AU  - Farhat MR
AU  - Gagneux S
AU  - Grobusch MP
AU  - Gröschel MI
AU  - Guglielmetti L
AU  - Kontsevaya I
AU  - Lange B
AU  - van Leth F
AU  - Lienhardt C
AU  - Mandalakas AM
AU  - Maurer FP
AU  - Merker M
AU  - Miotto P
AU  - Molina-Moya B
AU  - Morel F
AU  - Niemann S
AU  - Veziris N
AU  - Whitelaw A
AU  - Horsburgh CR Jr
AU  - Lange C
AU  - TBnet and RESIST-TB networks
PY  - 2023
JO  - The Lancet. Infectious diseases
DO  - 10.1016/s1473-3099(22)00875-1
UR  - https://doi.org/10.1016/s1473-3099(22)00875-1
ER  -

APA

J, D., MJ, B., E, C., D, C., F, C., V, C., K, D., A, D., MR, F., S, G., MP, G., MI, G., L, G., I, K., B, L., F, V. L., C, L., AM, M., FP, M., M, M., P, M., B, M., F, M., S, N., N, V., A, W., Jr, H. C., C, L., & networks, T. A. R. (2023). Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.. The Lancet. Infectious diseases. https://doi.org/10.1016/s1473-3099(22)00875-1

Source records

pubmed · retrieved 2026-09-26T07:42:11.497Z